International Normalized Ratio in patients not on vitamin K antagonists [3]

Journal of Thrombosis and Haemostasis

Volumn 5, Issue 1, 2007, Pages 188-189

  Keeling, David ^a  

^a British Committee for Standards in Haematology   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVITAMIN K; BIOLOGICAL MARKER; THROMBOPLASTIN;

BLOOD CLOTTING FACTOR DEFICIENCY; DISEASE SEVERITY; DRUG MONITORING; HUMAN; INTERNATIONAL NORMALIZED RATIO; LETTER; LIVER FAILURE; PRIORITY JOURNAL; PROTHROMBIN TIME; REFERENCE VALUE; STANDARDIZATION;

ANTICOAGULANTS; BLOOD COAGULATION; HUMANS; INDICATORS AND REAGENTS; INTERNATIONAL NORMALIZED RATIO; PRACTICE GUIDELINES; PROTHROMBIN TIME; REPRODUCIBILITY OF RESULTS; THROMBOPLASTIN; VITAMIN K;

EID: 33845536807     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2006.02286.x     Document Type: Letter

References (2)

1. WHO.Expert Committee on Biological Standardization. Thirty-third report. World Health Organ Tech Rep Ser 1983; 687: 1-184.
2. Kovacs MJ, Wong A, MacKinnon K, Weir K, Keeney M, Boyle E, Cruickshank M. Assessment of the validity of the INR system for patients with liver impairment. Thromb Haemost 1994; 71: 727-30.